A Single Center, Double-blind, Parallel-group, Two Factor Patient Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area

Trial Profile

A Single Center, Double-blind, Parallel-group, Two Factor Patient Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Deoxycholic acid (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Kythera Biopharmaceuticals
  • Most Recent Events

    • 02 Jul 2015 Protocol has been amended to change in treatment arms, incl/exclu criteria and primary endpoint.
    • 04 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 15 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top